According to Susan Bates the field of epigenetics has reached a very exciting point. For many years we only had drugs available for acute leukaemia and T-cell lymphomas. Now we can expand the number of drugs that actually affect chromatin and DNA.
At TAT 2018 Congress one exciting point was communication of the fact that a quarter of all cancers including breast cancer, colon cancer and all solid tumours have mutation of what we call the chromatin modulating agents or the chromatin modifiers.
We have the IDH2 inhibitor approved, IDH1 inhibitor will be next and we have another one studied, so I think we’ve got three new very solid drugs in the pipeline.
Produced by the European Society for Medical Oncology